Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

NCT00287092 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

807

Enrollment

INDUSTRY

Sponsor class

Conditions

Pertussis
Diphtheria
Tetanus
Poliomyelitis
Haemophilus Influenzae Type b

Interventions

BIOLOGICAL: DT5aP-IPV-Hib 5-component Pertussis vaccine
BIOLOGICAL: Infanrix® -IPV+Hib

Sponsor

Sanofi Pasteur, a Sanofi Company